{"data":{"ticker":"RXRX","slug":"recursion-pharmaceuticals","name":"Recursion Pharmaceuticals","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Salt Lake City, Utah","ceo":"Najat Khan","employees":600,"website":"https://www.recursion.com","founded":"2013","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"},{"slug":"foundation-models","name":"Foundation Models"}],"exposure":{"score":90,"tier":"Pure Play","rationale":"Recursion runs an AI drug discovery platform, pairing foundation models with massive automated biology datasets to industrialize target and molecule discovery, monetized through pharma partnerships and its own pipeline. The company exists as a bet that AI can decode biology, making it a pure play."},"quote":{"price":3.52,"change24hPct":0.57,"change7dPct":-12.66,"change30dPct":-10.89,"change1yPct":-23.81,"high52w":4.96,"low52w":2.84,"marketCap":2194254848,"peRatio":null,"eps":-0.86,"volume24h":54504704},"nextEarningsDate":"2026-11-02","summary":"Recursion Pharmaceuticals is a clinical-stage TechBio company trying to industrialize drug discovery. It pairs AI with enormous automated biology experiments, generating its own datasets and using models to decode how biology works. Revenue comes from pharma partnerships and, eventually, its own drug pipeline.","explainer":["Recursion Pharmaceuticals is a clinical-stage TechBio company trying to industrialize drug discovery. It pairs AI with enormous automated biology experiments, generating its own datasets and using models to decode how biology works. Revenue comes from pharma partnerships and, eventually, its own drug pipeline.","Its stack includes Recursion OS, the operating system tying automated labs to machine learning, the LOWE and Boltz foundation models trained on biological data, and its broader AI drug discovery platform that proposes targets and molecules for testing.","Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion trades on the NASDAQ and employs about 600 people under co-founder and CEO Najat Khan."],"buildoutRole":"Recursion sits in the AI Healthcare and Foundation Models layers as one of the clearest AI-native bets in biotech. It trains biological foundation models on datasets its own automated labs generate, releasing work such as the Boltz co-folding models openly while monetizing through pharma partnerships and its own pipeline. That makes AI the company rather than a tool inside it, which is why Supercycle scores its AI exposure at 90 out of 100.","faq":[{"q":"What does Recursion Pharmaceuticals do?","a":"Recursion is a clinical-stage TechBio company that industrializes drug discovery. It runs massive automated biology experiments, trains AI models on the resulting data, and monetizes through pharma partnerships and its own pipeline."},{"q":"How is Recursion exposed to AI?","a":"Almost entirely. The company is built as a bet that AI can decode biology, with foundation models and automated datasets at the core of everything it does. Supercycle rates its AI Exposure Score at 90 out of 100."},{"q":"What are Recursion's main products?","a":"Recursion OS, the platform connecting its automated labs to machine learning, LOWE foundation models trained on biological data, and its AI drug discovery platform for proposing targets and molecules."},{"q":"Is RXRX a pure play AI stock?","a":"Yes by Supercycle's rating. Recursion exists as an AI-first drug discovery bet, and its AI Exposure Score of 90 out of 100 places it in the top tier of the exposure leaderboard."},{"q":"Where is Recursion based and who leads it?","a":"Recursion is headquartered in Salt Lake City, Utah, and led by co-founder and CEO Najat Khan. Founded in 2013, the company employs about 600 people and its shares trade on the NASDAQ."}],"history1y":[{"date":"2026-09-28","close":3.7},{"date":"2026-09-29","close":4.03},{"date":"2026-09-30","close":4.13},{"date":"2026-10-01","close":4.07},{"date":"2026-10-02","close":4.12},{"date":"2026-10-05","close":4.78},{"date":"2026-10-06","close":4.63},{"date":"2026-10-07","close":4.27},{"date":"2026-10-08","close":3.95},{"date":"2026-10-09","close":4.36},{"date":"2026-10-12","close":4.01},{"date":"2026-10-13","close":3.84},{"date":"2026-10-14","close":3.74},{"date":"2026-10-15","close":4.16},{"date":"2026-10-16","close":3.46},{"date":"2026-10-19","close":3.61},{"date":"2026-10-20","close":3.66},{"date":"2026-10-21","close":3.64},{"date":"2026-10-22","close":3.58},{"date":"2026-10-23","close":3.7},{"date":"2026-10-26","close":3.8},{"date":"2026-10-27","close":4.05},{"date":"2026-10-28","close":4.35},{"date":"2026-10-29","close":4.24},{"date":"2026-10-30","close":4.03},{"date":"2026-11-02","close":3.83},{"date":"2026-11-03","close":3.68},{"date":"2026-11-04","close":3.88},{"date":"2026-11-05","close":3.5},{"date":"2026-11-06","close":3.52}],"incomeStatements":[{"ticker":"RXRX","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":74256000,"cost_of_revenue":70953000,"gross_profit":3303000,"operating_expense":0,"operating_income":-648132000,"net_income":-644759000,"earnings_per_share":-1.44,"earnings_per_share_diluted":-1.44,"research_and_development":475271000,"selling_general_and_administrative_expenses":176589000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"RXRX","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":58488000,"cost_of_revenue":45238000,"gross_profit":13250000,"operating_expense":0,"operating_income":-479004000,"net_income":-463661000,"earnings_per_share":-1.69,"earnings_per_share_diluted":-1.69,"research_and_development":314421000,"selling_general_and_administrative_expenses":178184000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"RXRX","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":43876000,"cost_of_revenue":42587000,"gross_profit":1289000,"operating_expense":0,"operating_income":-350060000,"net_income":-328066000,"earnings_per_share":-1.58,"earnings_per_share_diluted":-1.58,"research_and_development":241226000,"selling_general_and_administrative_expenses":110822000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"RXRX","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":39681000,"cost_of_revenue":48275000,"gross_profit":-8594000,"operating_expense":0,"operating_income":-245727000,"net_income":-239476000,"earnings_per_share":-1.36,"earnings_per_share_diluted":-1.36,"research_and_development":155696000,"selling_general_and_administrative_expenses":81599000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"RXRX","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":1474130000,"current_assets":812845000,"cash_and_equivalents":743294000,"total_liabilities":343265000,"current_liabilities":147707000,"total_debt":77965000,"shareholders_equity":1130865000,"retained_earnings":-2076002000},{"ticker":"RXRX","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":1448598000,"current_assets":714269000,"cash_and_equivalents":594350000,"total_liabilities":413816000,"current_liabilities":187472000,"total_debt":108492000,"shareholders_equity":1034782000,"retained_earnings":-1431283000},{"ticker":"RXRX","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":653699000,"current_assets":438137000,"cash_and_equivalents":391565000,"total_liabilities":190263000,"current_liabilities":93171000,"total_debt":50672000,"shareholders_equity":463436000,"retained_earnings":-967622000},{"ticker":"RXRX","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":701288000,"current_assets":569814000,"cash_and_equivalents":549912000,"total_liabilities":215482000,"current_liabilities":100265000,"total_debt":51005000,"shareholders_equity":485806000,"retained_earnings":-639556000}],"holders13f":[{"slug":"cathie-wood","personName":"Cathie Wood","fundName":"ARK Investment Management","value":151709111,"portfolioPct":0.009849917704101353,"change":"increased","period":"2026-06-30"},{"slug":"softbank","personName":"SoftBank Group","fundName":"SoftBank Group","value":50046010,"portfolioPct":0.002753632778162515,"change":"unchanged","period":"2026-06-30"},{"slug":"ray-dalio","personName":"Ray Dalio","fundName":"Bridgewater Associates","value":138238,"portfolioPct":0.0000056710497737144355,"change":"new","period":"2026-06-30"}],"news":[{"title":"Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/recursion-pharmaceuticals-rxrx-bargain-q3-081601198.html?.tsrc=rss","date":"2026-11-05"},{"title":"REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock","source":null,"url":"https://finance.yahoo.com/healthcare/articles/rec-4881-trial-results-could-001509350.html?.tsrc=rss","date":"2026-11-05"},{"title":"Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 Win","source":null,"url":"https://finance.yahoo.com/healthcare/articles/recursion-pharmaceuticals-rxrx-puts-fred-221532968.html?.tsrc=rss","date":"2026-11-04"},{"title":"RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway","source":null,"url":"https://finance.yahoo.com/healthcare/articles/rxrx-q3-earnings-call-highlights-140000731.html?.tsrc=rss","date":"2026-11-04"},{"title":"Recursion Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary","source":null,"url":"https://app.moby.co/home/research/tools/earningsCalendar/earnings-recursion-pharmaceuticals-inc-q3-2026-earnings-call-summary?utm_source=yahoo_finance&utm_medium=rss&.tsrc=rss","date":"2026-11-03"},{"title":"Recursion (RXRX) Q3 2026 Earnings Call Transcript","source":null,"url":"https://www.fool.com/earnings/call-transcripts/2026/11/03/recursion-rxrx-q3-2026-earnings-call-transcript/?.tsrc=rss","date":"2026-11-03"},{"title":"What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call","source":null,"url":"https://www.marketbeat.com/instant-alerts/transcript-what-recursion-pharmaceuticals-rxrx-said-on-its-q3-earnings-call-2026-11-03/?utm_source=yahoofinance&utm_medium=yahoofinance&.tsrc=rss","date":"2026-11-03"},{"title":"Recursion Pharmaceuticals: Q3 Earnings Snapshot","source":null,"url":"https://finance.yahoo.com/healthcare/articles/recursion-pharmaceuticals-q3-earnings-snapshot-043740524.html?.tsrc=rss","date":"2026-11-03"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.748Z","tier":"free","source":"https://supercyclehq.com/stock/recursion-pharmaceuticals","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/RXRX","html":"https://supercyclehq.com/stock/recursion-pharmaceuticals","md":"https://supercyclehq.com/stock/recursion-pharmaceuticals.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}